Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Ariad Pharmaceuticals, Inc. | ARIA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 23.99 | 0.00 | 0.00 | 0.00 | 23.99 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 23.80 | 22.88 | -0.92 | -4.02% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Ariad Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 4.54B | 189.10M | $ -231.16M | -1.22 | 202.46 | 189.10M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Ariad News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARIA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0 | 0 | 0 | 0.0000 | - | - | - |
| 1 Month | 0 | 0 | 0 | 0.0000 | - | - | - |
| 3 Months | 0 | 0 | 0 | 0.0000 | - | - | - |
| 6 Months | 0 | 0 | 0 | 0.0000 | - | - | - |
| 1 Year | 0 | 0 | 0 | 0.0000 | - | - | - |
| 3 Years | 0 | 0 | 0 | 0.0000 | - | - | - |
| 5 Years | 0 | 0 | 0 | 0.0000 | - | - | - |
Ariad Description
| Ariad Pharmaceuticals is a biotechnology company with a focus on cancer drugs. The global oncology company aims to discover, develop, and commercialize small-molecule medicines to treat aggressive cancers where current therapies are inadequate, including leukemia. The vast majority of Ariad's revenue is derived from its product revenue segment, followed by its license collaboration and other revenue segments. The United States represents a majority of the company? oncology profits based on roughly half of its global sales. Ariad seeks market share outside the U.S. through industry partnerships. |
